QTTB Stock Forecast: Q32 Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.34
−1.65% on the day

The median 12-month analyst price target for Q32 Bio, Inc. is $38. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$249.6M
Ticker Nerd rank
61/ 100
Median analyst target
$38
Analysts covering
7
Revenue$0.0
Operating income−$9.1M
Net income−$8.9M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−3.2%
YTD
+151.2%
1Y
+332.1%
From 52W high
−61.0%
From 52W low
+332.1%
$2
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Q32 Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
61/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
87
Momentum
79
Growth
67
Revisions
63
Volatility
60
Issuance
45
Value
22
Accruals
11

Quality (87): The business earns solid, repeatable profits on what it owns.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

QTTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26QTTBHigh $59Median $38Low $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$29
Low
$38
Median
$59
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026Leerink PartnersInitiatesOutperform$40
28 Sept 2026JefferiesInitiatesBuy$29
24 Aug 2026Morgan StanleyInitiatesOverweight$34
28 July 2026HC Wainwright & Co.MaintainsBuy$13 → $36
13 July 2026OppenheimerMaintainsOutperform$20 → $40
13 July 2026Wells FargoUpgradeOverweight$66
22 May 2026MizuhoInitiatesOutperform$14
18 May 2026Cantor FitzgeraldInitiatesOverweight—
5 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright & Co.InitiatesBuy—
12 Mar 2025Wells FargoMaintainsEqual-Weight—
11 Feb 2025BMO CapitalDowngradeMarket Perform—
11 Feb 2025Piper SandlerDowngradeNeutral—
12 Dec 2024BMO CapitalMaintainsOutperform—
12 Dec 2024GuggenheimDowngradeNeutral—
11 Dec 2024Leerink PartnersDowngradeMarket Perform—
11 Dec 2024OppenheimerMaintainsOutperform—
11 Dec 2024Piper SandlerMaintainsOverweight—
11 Dec 2024Raymond JamesDowngradeOutperform—
11 Dec 2024Wells FargoDowngradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QTTB.

Market Radar

This page is one stock. Monday covers all of them.

QTTB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

QTTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Q32 Bio, Inc. returned +332.1% against +6.9% for the S&P 500, dividends included.

QTTB vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26QTTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QTTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 90% of US stocks

Price / sales
4.6×

Cheaper than 23% of US stocks

Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
34.2%

Higher than 90% of US stocks

Net margin
60.0%

Higher than 97% of US stocks

Returns & dividend
Return on equity
24.0%

Higher than 84% of US stocks

Return on assets
6.5%

Higher than 82% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Q32 Bio, Inc. has a market value of $249.6M.

  • Revenue in the twelve months to 30 June 2026: $53.7M.

  • Net income over the same four quarters: $33.8M, a 62.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.8M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: 2.3×.

  • Q32 Bio, Inc. employs 25 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

QTTB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QTTBQ32 Bio, Inc.$249.6M61
TTRXTurn Therapeutics, Inc.$247.5M24
LXEOLexeo Therapeutics, Inc.$245.1M30
EDITEditas Medicine, Inc.$251.7M67
SABSSAB Biotherapeutics, Inc.$255.7M47
EIKNEikon Therapeutics, Inc.$256.4M5
PRLDPrelude Therapeutics, Inc.$257.3M92

Take a look at QTTB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Q32 Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about QTTB

What is the QTTB stock price forecast for 2026-2027?

The median 12-month analyst price target for Q32 Bio, Inc. is $38, with estimates ranging from $29 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTTB stock a buy right now?

Of the 7 analysts covering Q32 Bio, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Q32 Bio, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTTB?

As at 21 Nov 2026, Q32 Bio, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (87 of 100).

Will QTTB stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $38, and Ticker Nerd's factor model ranks Q32 Bio, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTTB stock forecast for 2030?

No analyst covering Q32 Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $59 over the next 12 months.

How has QTTB stock performed over the past year?

Q32 Bio, Inc. returned +332.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Q32 Bio, Inc. do?

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions.

Company

About Q32 Bio, Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.

CEO Ms. Jodie Pope Morrison · 25 employees · United States · https://www.q32bio.com